CDTX - Cidara doses first group in phase 1 trial of CD388 for treating/preventing influenza

Cidara Therapeutics (NASDAQ:CDTX) dosed the first cohort of healthy volunteers in a phase 1 trial of its antiviral immunotherapy CD388 for preventing seasonal and pandemic influenza. The study is being conducted under an exclusive worldwide license and collaboration agreement with Johnson & Johnson's (JNJ) Janssen Pharmaceuticals to develop and sell Cidara’s Cloudbreak drug-Fc conjugates (DFCs), such as CD388, for preventing and treating seasonal and pandemic influenza. The early-stage trial, which dosed its first healthy volunteer in mid-March, is to determine the safety, tolerability and pharmacokinetics of intramuscular and subcutaneous administration of CD388 in healthy people. The trial is advancing to dosing subsequent groups. Initial data from the study is expected in H2 2022.

For further details see:

Cidara doses first group in phase 1 trial of CD388 for treating/preventing influenza